For #Investors:

We’ll be sharing our 9M and Q3 2026 performance update at 07:00 GMT on 30 October 2026.

An accompanying webcast for investors and analysts will take place at 14:30 GMT. Register to attend virtually here: learn.az/6016BHkNas

$AZN

🧬Today marks the opening of our new global R&D centre in Cambridge, Massachusetts, US.

Bringing together exceptional talent and cutting-edge technologies to help accelerate scientific discovery and advance the next generation of medicines. Learn more: learn.az/6016BGLoRQ

$AZN #WhatScienceCanDo

At #ClimateWeekNYC, we shared how partnership is critical for healthier people, health systems and the planet.

Highlights included: our $100m Young Health Programme commitment, a new tool that models the environmental impact of care pathways and the European Network on Climate aching 6,000 medical students.

Thanks to colleagues, partners and young leaders who made this progress possible.

We’re investing more than $100m in our Young Health Programme 2010 to 2030, in partnership with @UNICEF and 60 NGO partners.

By 2030, the programme aims to reach 10m more young people in underserved communities and train 800,000 youth advocates. Learn more: learn.az/6016BGdXUg

#YoungHealthProgramme

Patient care delivery accounts for around 40% of emissions from the healthcare sector.

Today we're launching CARESA, a free tool that helps health systems estimate the environmental footprint of care pathways and explore opportunities for more sustainable care🌍 bdSQX

Named #5 in TIME’s World’s Best Companies and ranked #1 in our industry 🌍

Behind this recognition: 96,000+ colleagues, partners and suppliers working together for people, society and the planet.

learn.az/6013BGKaxt

#WhatScienceCanDo #TIME #WorldsBestCompanies

32 young leaders from 24 countries. One shared goal: better health.

Meet our 2026 Young Health Programme Impact Fellows and Scholars taking action on health equity, health systems resilience and climate and nature.

With @OneYoungWorld and @YouthAssembly.

#YoungHealthProgramme

Since our FY 2025 results, our pipeline has delivered 6 key positive Phase III programmes and 8 first approvals in major markets.

Learn more: learn.az/6012BEvvGp

#AZN #FinancialResults $AZN

In H1 2026, Core EPS increased 11% reflecting strong commercial execution and confidence in our long-term outlook.

Learn more: learn.az/6012BEvvGp

#AZN #FinancialResults $AZN

Our H1 2026 results demonstrate that we are on track to deliver our $80bn Total Revenue ambition and drive growth beyond 2030.

Learn more: learn.az/6012BEvvGp

#AZN #FinancialResults $AZN

For #Investors and #Media only.

Our H1 2026 results are now available, highlighting strong growth momentum, with Total Revenue up 6% and continued pipeline delivery.

Learn more: learn.az/6012BEvvGp

#AZN #FinancialResults $AZN

Named among @TIME World's Most Sustainable Companies for the third consecutive year.

Sustainability is embedded in our strategy and how we operate — helping us build a more resilient, efficient business as we deliver life-changing medicines and support a healthier future for
Learn more: learn.az/6013BDj2gd

#WhatScienceCanDo

We focus on advancing research and understanding of generalised myasthenia gravis (MG), guided by those affected and aiming to improve care and outcomes.

#MGAwarenessMonth #MyastheniaGravis #RareDiseases

Today we rang the opening bell at @NYSE to mark our recent share listing and harmonised trading across New York, London and Stockholm. This moment reflects the science, innovation and teamwork helping us turn bold ideas into life-changing medicines.

#AZN #WhatScienceCanDo

Named one of @FinancialTimes Europe’s Climate Leaders for the 6th consecutive year.

Our $1bn Ambition Zero Carbon programme has delivered:

↘️88% cut in Scope 1 & 2 emissions

🔋81% EV fleet

💡80%+ supplier spend with SBT partners.

Read more: ft.com/content/1d4be2…

#WhatScienceCanDo

This Eosinophilic Diseases Awareness Month, we're calling for earlier diagnosis, better care and continued progress for people living with eosinophilic diseases such as eosinophilic esophagitis (EoE).

#EAM2026 #WorldEOEDay

For investor audiences and business/financial media only 📈

We delivered strong growth in Q1 2026 with Total Revenue above $15 billion, demonstrating our consistent commercial execution as we transform patient care.

Learn more: astrazeneca.com/media-centre/p…

#AZN #FinancialResults

Receiving a rare disease diagnosis often takes five years and involves multiple doctors, specialists, and misdiagnoses.
Improving the diagnostic process can help shorten this journey for the rare disease community. #RareDisease

We highlight the neuromyelitis optica spectrum disorder (NMOSD) community and share insights to support understanding and collaboration in healthcare.

#NMOAwarenessMonth #NMOSD #RareDisease

Rare Disease Day (28 Feb) is a global call to act for more than 400 million people living with rare conditions and their caregivers.

Learn how we listen to and partner with the rare disease community to speed up access to diagnosis and equitable care: learn.az/6017hmwt9

More than 10,000 rare diseases affect over 400 million people worldwide. Fewer than 10% of these conditions have an approved treatment. Developing and delivering innovative therapies is essential to reach more people in need. #RareDisease

#News for #Investors and #Media📈

2025 was another year of strong growth with excellent pipeline delivery across all therapy areas and major regions.

Watch our CEO Pascal Soriot share our FY 2025 results and learn more: learn.az/6013h3PrH

#AZN #FinancialResults

Newborn screenings and genetic testing play a critical role in accelerating diagnosis and reducing healthcare costs, yet access remains limited. Expanding availability of these diagnostic tools can support earlier diagnosis of rare diseases. #RareDisease

#News
Exciting news—we are now trading our ordinary shares on the New York Stock Exchange (NYSE) for the first time, aligning trading across the NYSE, London Stock Exchange (LSE), and Nasdaq Stockholm (STO) under a harmonised global listing structure.

#AZN

While the definition of a rare disease varies across countries, the number of people affected remains significant. Improving equitable access to healthcare for those living with rare diseases is essential. #RareDisease

Exciting news: AstraZeneca has been named Pharma Company of the Year at the 2025 SCRIP Awards. This recognition reflects our commitment to helping transform the future of healthcare and delivering potentially life-changing medicines to patients.

#ASH25 may be over, but the collaboration to develop new treatments for patients with blood cancers continues. Our haematology leaders share their perspectives on how scientific innovation and bold ambition are shaping future approaches to blood cancer care. #Haematology

#News We announced plans to invest $2 billion to expand our manufacturing footprint in Maryland, part of the $50 billion US commitment made in July. Supporting 2,600 jobs, strengthening US medicines supply chain, and accelerating access to transformative therapies. #AZN

#News for #Investors and #Media📈
Our 9M & Q3 results are now available and show strong momentum, with Total Revenue up 11% and excellent pipeline delivery: learn.az/601973eAt

#AZN #FinancialResults

We highlight the hypophosphatasia (HPP) community and share insights into the daily challenges of this rare metabolic condition.

Listening to and learning from this patient community supports progress in HPP care.
#WorldHPPDay #Hypophosphatasia #RareDisease

#ESMO25 highlighted why we do what we do — driving innovation, impact and hope for patients.

Thank you to the global oncology community for advancing progress and pushing boundaries.

On #GlobalPNHAwarenessDay, we’re joining the #RareDisease community around the world to bring attention to paroxysmal nocturnal hemoglobinuria (#PNH).

By deepening awareness and understanding of this rare disease, we’re committed to improving outcomes for those living with PNH.

We’re proud to announce a historic agreement with @POTUS to lower the cost of prescription medicines for American patients while preserving the America’s cutting-edge biopharmaceutical innovation. Learn more: learn.az/6014AQPWK #AZN #News

#News Today we announced we will invest US$4.5 billion in a new manufacturing facility in Virginia— which includes a proposed $500m increase to enhance manufacturing capabilities to bring a broader range of medicines, including cancer, to patients in the US and worldwide.

#AZN

We’re pushing the boundaries of science to redefine outcomes, reduce economic burden and prioritize prevention in respiratory and other immune-mediated diseases. Our goal is that every patient gets the care they need and deserve. Read more: learn.az/6015Aj14z

On #aHUSDay, we recognise those living with atypical haemolytic uraemic syndrome. We are inspired by the strength and resilience of the #aHUS community and remain dedicated to improving care for those affected by this severe and devastating disease. #aHUS24Sept

Meet the 2025 #YoungHealthProgramme changemakers! From Impact Fellows to Scholars, these young leaders are advancing health equity around the world.

Partnering with @OneYoungWorld & @AFSyouthassembly to support the next generation.

#News for #Investors and #Media📈

Our H1 results are now available and show strong momentum, with Total Revenue up 11% and remarkable pipeline delivery.

learn.az/6010fRVfk

#AZN #FinancialResults

#News for #investors and #media

We’re investing $50 billion in medicines manufacturing and R&D in the US by 2030, including the largest single manufacturing investment we’ve ever made—a new state-of-the-art drug substance manufacturing centre in Virginia.

#AZN

Explore our Sustainability Impact Publication which highlights how we're taking action on climate and nature, health equity and health systems resilience. Through collaboration, we can build a healthier future for people, society & planet: learn.az/6014N4J9E

#News for #Investors and #Media📈

We continued our strong growth momentum into 2025 with Total Revenue increasing by 10%, driven by double-digit growth across Oncology/ Haematology and BioPharmaceuticals.

#AZN #FinancialResults

🌍 Calling all youth leaders in global health equity! Join our Young Health Programme Impact Fellowship for a fully funded @OneYoungWorld scholarship, financial grant, and development opportunities.

Apply now: learn.az/6018FZLFp

#OYW25 #YoungHealthProgramme

Are you a young leader advocating for greater health equity? Now’s the time to apply to the Young Health Programme Impact Fellowship in partnership with @OneYoungWorld: learn.az/6011LU8TU

#YoungHealthProgramme
#OYW25

2024 was another year of double-digit growth with continued scientific progress across all Therapy Areas. Our total annual dividend increased by 7% to $3.10 per share and will further increase in 2025.

Watch CEO Pascal Soriot share our Full Year and Q4 2024 results. #AZN

We’re setting new standards in sustainable science, becoming the first organisation to achieve the new
@My_Green_Lab 2.0 Certification. We have over 78 lab spaces certified and 65 achieved the highest certification level – Green.

#WhatScienceCanDo #GreenLabs #RacetoZero

From lab to patient, we’re focused on sustainable science and leveraging digital advances such as electronic product information (ePI), unlocking benefits for people, society and the planet. Learn more: learn.az/6010Q1ZU0

COPD is responsible for 425 deaths every hour. You can help change this statistic. Early detection and diagnosis paired with timely access to comprehensive care can reduce the burden.

This #WorldCOPDDay, take a stand against COPD: learn.az/6016s6eBC

#SpeakUpforCOPD

We’re supporting the launch of a new Patient Charter, calling for improvements in the quality of care for those living with systemic lupus erythematous. Learn more on how the lupus community is uniting to drive change: learn.az/6019S4p5z

Our #YoungHealthProgramme Impact Fellows attended @OneYoungWorld, and developed their global network of young leaders. Learn more here:

learn.az/6017ST3R5

#OYW24

The landscape of lupus care is changing rapidly, yet challenges to care persist. Profs. Ian Bruce and Julia Weinmann-Menke discuss how the current state of lupus care can be transformed to make achieving lasting remission a priority learn.az/6013Sp5T3

We’re driving sustainable science, ensuring that our clinical trials
represent the diversity of the communities we serve.

Discover more: learn.az/6010SJWmm

#WhatScienceCanDo

Digital biomarkers can help scientists better understand #RareDiseases and develop medicines to address unmet treatment needs. Learn more about this powerful research tool: learn.az/6018UOJma

#WhatScienceCanDo

As part of our commitment to sustainable science and innovation, we’re accelerating progress towards net zero by decarbonising our clinical trials. 🌍

Learn more: learn.az/6018WHoPA

#WhatScienceCanDo

🌟 Big news! We've been honoured with the Corporate Social Responsibility Programme of the Year at the Pharma Industry UK Awards 2024 and a Bronze for Best Community Involvement at the Corporate Engagement Awards 2024.

Proud moment for our team!

#YoungHealthProgramme

We’re following the science to better understand the complex pathways behind immune-driven diseases, such as cutaneous lupus erythematosus (CLE).

Through more targeted and proactive approaches, we aim to transform outcomes for patients.

Learn more: learn.az/6014oPThQ

The human and economic impact of chronic respiratory diseases like asthma and COPD continues to grow. Leading experts outline why earlier, more proactive intervention is needed to improve outcomes for patients, society, and the planet. Learn more: learn.az/6011WC7eU.

New research in Nature Genetics introduces MILTON, a cutting-edge machine-learning research tool that accelerates drug targets and biomarkers discovery, with potential to redefine the landscape of preventative health care: learn.az/6017WsgZD

Momentum is building to tackle chronic obstructive pulmonary disease (COPD). Together with our partners, we have launched The Global State of COPD Report, offering insights for policymakers to reduce the growing COPD burden. Learn more: learn.az/6011WMKtV #SpeakUpForCOPD.